Though the role of YAP1 in parathyroid adenomas needs to be further elucidated, these results expand intracellular signaling aberrations characterizing parathyroid tumors and coupled to CASR, suggesting new targets for medical treatment of parathyroid tumors, which represents an unmet clinical need in the management of both benign and malignant parathyroid tumors. Here, CASR is linked to parathyroid gland adenoma.